Osner Etienne, APRN
Psychiatric/Mental Health · Hollywood, FLNPI 1942807367
Payments from drug & device makers
Across 797 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Neurocrine Biosciences, Inc.$1K
- AbbVie$1K
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- plus $8K from 28 others
What the payments were for
- Food & beverage$16,497100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 73 | $1,534 |
| Neurocrine Biosciences, Inc. | 48 | $1,435 |
| AbbVie | 79 | $1,432 |
| Alkermes, Inc. | 65 | $1,316 |
| Teva Pharmaceuticals USA, Inc. | 91 | $1,302 |
| Otsuka America Pharmaceutical, Inc. | 57 | $1,285 |
| Axsome Therapeutics, Inc. | 37 | $962 |
| Indivior Inc. | 42 | $936 |
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $872 |
| Almatica Pharma LLC | 42 | $822 |
| Johnson & Johnson | 40 | $738 |
| Vanda Pharmaceuticals Inc. | 29 | $729 |
| Bausch Health US, LLC | 30 | $588 |
| Corium, LLC | 27 | $540 |
| Idorsia Pharmaceuticals US Inc | 14 | $406 |
| Sunovion Pharmaceuticals Inc. | 16 | $326 |
| Lundbeck LLC | 14 | $273 |
| Braeburn Inc. | 9 | $178 |
| Orexo US, Inc. | 9 | $169 |
| Supernus Pharmaceuticals, Inc. | 7 | $108 |
| E.r. Squibb & Sons, L.L.C. | 4 | $96 |
| Ironshore Pharmaceuticals Inc. | 4 | $79 |
| Collegium Pharmaceutical, Inc. | 4 | $74 |
| Jazz Pharmaceuticals Inc. | 2 | $42 |
| Noven Therapeutics, LLC | 2 | $36 |
| Luye Pharma (USA) Ltd. | 2 | $34 |
| Merck | 2 | $34 |
| Tempus AI, Inc | 1 | $29 |
| Astellas Pharma US Inc | 1 | $25 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Tris Pharma Inc | 1 | $21 |
| Alfasigma USA, Inc. | 1 | $18 |
| Neos Therapeutics, LP | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,497 in reported general payments places this provider in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 17 | $136,469 |
| Invega SustennaPaliperidone Palmitate | 13 | $31,811 |
| VraylarCariprazine Hcl | 12 | $16,736 |
| RexultiBrexpiprazole | 11 | $16,538 |
| XanaxAlprazolam | 12 | $10,607 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $8,315 |
| Adzenys Xr-OdtAmphetamine | 12 | $5,995 |
| QuviviqDaridorexant Hcl | 11 | $5,472 |
| Loreev XrLorazepam | 11 | $4,198 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 29 | $3,750 |
| Trazodone Hcl | 196 | $2,788 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 95 | $1,848 |
| Quetiapine Fumarate | 168 | $1,844 |
| Bupropion Hcl SrBupropion Hcl | 144 | $1,492 |
| Duloxetine Hcl | 84 | $1,388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,435 | $136,46917 claims |
| Johnson & JohnsonInvega Sustenna | $738 | $31,81113 claims |
| AbbVieVraylar | $1,432 | $16,73612 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,285 | $16,53811 claims |
| Neos Therapeutics, LPAdzenys Xr-Odt | $18 | $5,99512 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $406 | $5,47211 claims |
| Almatica Pharma LLCLoreev Xr, Sertraline Hcl | $822 | $4,696156 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,096 psychiatric/mental health providers in Florida.
Other psychiatric/mental health in Hollywood
- Cindy DerequitoHollywood$18K
- Maria PimentelHollywood$18K
- Raphael PalaciosHollywood$16K
- Nafeeza AlliHollywood$15K
- Roger RiveraKissimmee$1.6M
- Bethanie Simmons BecilJacksonville$782K
- Hannah PhillipsMaitland$455K
- Cheedy JajaTampa$266K
- Scott DurrancePensacola$224K
- Eudaldo AponteHialeah$214K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.